Literature DB >> 3317103

Antigenic expression by cells derived from human gliomas does not correlate with morphological classification.

P G Kennedy1, B A Watkins, D G Thomas, M D Noble.   

Abstract

We have found that cell populations derived from human gliomas can be divided into antigenic classes which are not predictable on the basis of standard morphological analysis and which, most frequently, do not support the lineage assignations of various tumours as determined by traditional neuropathological methods. For example, only 6/60 cultures derived from astrocytomas expressed glial fibrillary acidic protein (GFAP), an astrocyte specific marker, and all six of these cultures were derived from morphological categories which more frequently gave rise to populations which did not express GFAP. None of the seven oligodendrogliomas or four oligo-astrocytomas examined expressed antigens specifically expressed by oligodendrocytes. Most tumour-derived populations, from all classes of tumour and all grades of malignancy, expressed cell-surface fibronectin, an extracellular matrix protein only rarely found on the surfaces of CNS macroglia; such cells did not express glial-specific antigens (e.g., GFAP) in vitro. Investigation of antigen expression in tumour biopsies indicated that some tumours also consisted largely or wholly of cells which expressed fibronectin in situ. Fibronectin-expressing cells were aneuploid and were not contact inhibited in their growth, indicating that they were transformed cells. We have also identified two previously unknown antigenic phenotypes among the gliomas.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3317103     DOI: 10.1111/j.1365-2990.1987.tb00190.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  16 in total

1.  Changes in glial fibrillary acidic protein and karyotype during culturing of two cell lines established from human glioblastoma multiforme.

Authors:  V Bocchini; R Casalone; P Collini; G Rebel; F Lo Curto
Journal:  Cell Tissue Res       Date:  1991-07       Impact factor: 5.249

2.  Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas.

Authors:  Sergei I Bannykh; C Claus Stolt; Jung Kim; Arie Perry; Michael Wegner
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

3.  My life as a clinician-scientist: trying to bridge the perceived gap between medicine and science.

Authors:  Peter G E Kennedy
Journal:  DNA Cell Biol       Date:  2015-03-31       Impact factor: 3.311

Review 4.  Glial ontogeny and glial neoplasia: the search for closure.

Authors:  M E Linskey
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

5.  Glycolipids and myelin proteins in human oligodendrogliomas.

Authors:  C C Sung; R Collins; J Li; D K Pearl; S W Coons; B W Scheithauer; P C Johnson; A J Yates
Journal:  Glycoconj J       Date:  1996-06       Impact factor: 2.916

6.  Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors.

Authors:  Q R Lu; J K Park; E Noll; J A Chan; J Alberta; D Yuk; M G Alzamora; D N Louis; C D Stiles; D H Rowitch; P M Black
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

Review 7.  Growth factors, glia and gliomas.

Authors:  M Noble; M Mayer-Pröschel
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

8.  Dual lineage of astrocytomas.

Authors:  M Bishop; S M de la Monte
Journal:  Am J Pathol       Date:  1989-09       Impact factor: 4.307

Review 9.  Pathology and molecular genetics of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Andreas von Deimling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

10.  Anti-human Olig2 antibody as a useful immunohistochemical marker of normal oligodendrocytes and gliomas.

Authors:  Hideaki Yokoo; Sumihito Nobusawa; Hirohide Takebayashi; Kazuhiro Ikenaka; Koji Isoda; Makoto Kamiya; Atsushi Sasaki; Junko Hirato; Yoichi Nakazato
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.